cyrilzakka/clinical-trials huggingface dataset:
Carbohydrate Counting and DASH Intervention Among Children With Diabetes and Celiac Disease.

Study is an interventional clinical trial. children (aged 6-18 years) diagnosed with type 1 diabetes and celiac disease will be recruited conveniently from Endocrinology pediatric clinic at Prince Hamzah Hospital. Amman, Jordan. A sample of 45 diagnosed children, who will meet the inclusion criteria and will be agreed to participate will be centrally randomized to follow carbohydrate counting with GFD dietary intervention, carbohydrate counting with GFD and DASH dietary intervention, and control dietary intervention.

the main objective of this study to compare the effects of three diets: carbohydrate count with gluten-free diet, DASH and carbohydrate count with gluten-free diet, and gluten-free diet alone on glycemic control, growth rate, and the quality of life of 45 individual patients diagnosed with diabetes and celiac disease, who are receiving care in Prince Hamzah Hospital, and aged between 6-18 years, will be enrolled in this study. the duration of the follow-up will be up to ( 9 months); starting from the first interview and enrollment till reaching 9 months from the intervention. all the biochemical tests that are routinely measured will be recorded for each patients during the follow-up duration. these biochemical tests will be, mainly hemoglobin A1C, serum glucose, tissue-trans glutamines IgA( TTG IgA), vitamin D, calcium, phosphorus, and acute intermittent porphyria ( AIP) and will be recorded at baseline, after 6 months and at the end of the study (12 months). growth rate, and quality of life will be also assessed at based line, after 6 months and at the end of the study.

Eligibility Criteria:
Inclusion Criteria: 1- Jordanian children aged between 6 to 18 years old . 2- diagnosed with diabetes type 1 and celiac disease together. -

Exclusion Criteria: 1- any children diagnosed with celiac disease alone. 2- any children diagnosed with type 1 diabetes alone. 3- any children with different disease.

-
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis

This Phase 3 study has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.


Eligibility Criteria:
Inclusion Criteria:

* Subject has a clinical diagnosis of stable plaque psoriasis involving a minimum of 2% and no more than 12% affected body surface area.
* Subject has an Investigator's Global Assessment (IGA) score of at least three (moderate) at study start.
* If subject is a woman of childbearing potential, she must have a negative urine pregnancy test and agree to use an effective form of birth control for the duration of the study.

Exclusion Criteria:

* Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.
* Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis.
* Subject has a physical condition which, in the investigator's opinion, might impair evaluation of plaque psoriasis, or which exposes the subject to an unacceptable risk by study participation.
* Subject has used any phototherapy (including laser), photo-chemotherapy or other forms of photo based therapy for the treatment of their psoriasis within 30 days prior to study start.
* Subject has used any systemic methotrexate, retinoids, systemic corticosteroids \[including intralesional, intra-articular, and intramuscular corticosteroids\], cyclosporine or analogous products within 90 days prior to study start.
* Subject has used any systemic biologic therapy (i.e., FDA-approved or experimental therapy) within five half-lives of the biologic prior to study start.
Multimedia Education for Frail Patients

The goal of this clinical trial is to explore the impact of precision health care interventions on inpatients in acute medical institutions regarding their risk of falls, management, and prevention knowledge, as well as the incidence of falls among these patients. The main questions it aims to answer are:

What is the effectiveness of precision health care interventions on inpatients' knowledge of fall risk in acute medical institutions? What is the effectiveness of precision health care interventions on inpatients' knowledge of fall management in acute medical institutions? What is the effectiveness of precision health care interventions on inpatients' knowledge of fall prevention in acute medical institutions?

Frailty relates to the concept of physical deterioration associated with the aging process, which includes a weakening of the physiological and integrated physical strength of the body, its reserve and resistance to stressors, resulting in poor health, such as loss of physical and mental performance. Frailty is an important health care topic in patients with geriatric syndromes. Once the elderly enter the early stage of frailty, they are likely to fall repeatedly. Studies have shown that frailty and premature aging are important predictors of falls in the elderly. Therefore, professional medical staff should use frailty assessment indicators as early as possible to assess the possibility of frailty among the elderly in medical institutions or communities. At the same time, effective prevention strategies should be adopted to prevent reduce the incidence of falls due to frailty and improve the quality of life of patients and the elderly. Therefore, assessment of possible falls and frailty risks is a priority in acute care settings.

Eligibility Criteria:
Inclusion Criteria:

1. Patients admitted to general acute wards and surgical patients
2. Fall assessment score ≥ 3% of the high-risk group for falls

Exclusion Criteria:

1. Patients who were bedridden for a long time before admission
2. Patients suffering from mental illness
3. The patient or primary caregiver cannot respond effectively
Study of Psychiatric Aspects in Women With Lower Urinary Tract Symptoms

To identify the differences in psychopathology, personality traits among different female LUTS subtypes.


Eligibility Criteria:
Inclusion Criteria:

* all cases with lower urinary tract symptoms

Exclusion Criteria:

* nil
Evaluation and Detection of Facial Propionibacterium Acnes Bacteria and Phage

This multi-center, outpatient study will extract and evaluate the presence of facial P. acnes bacteria and phage strains using pore strips on up to 400 human subjects.

This multi-center, outpatient study will extract and evaluate the presence of facial P. acnes bacteria and phage strains using pore strips on up to 400 human subjects. An additional P. acnes visual detection method (VISIOPOR ® PP34N) will be used in this study as per PI decision to explore whether there is a correlation between P. acnes bacterial presence and fluorescent signal.

Eligibility Criteria:
Inclusion Criteria:

1. Adults between 14 to 50 years of age inclusive at the time of signing the informed consent
2. Able to provide written informed consent
3. Subjects who are willing to undergo pore strip treatment using the cosmetically acceptable pore strip product
4. Subjects who are willing to provide comprehensive demographic data using questionnaires

Exclusion Criteria:

1. Unwilling or unable to follow the procedures outlined in the protocol
2. Subjects treated with isotretinoin or tretinion during the 6 months prior to visit 1
3. Subjects treated with immunosuppressant agents
4. Pregnant subjects
Efficacy and Safety of Azimilide for the Treatment of Patients With Atrial Fibrillation

Atrial fibrillation (abnormal rhythm in the upper chamber of the heart) is a common supraventricular arrhythmia (abnormal heart rhythm) for which antiarrhythmic therapy is often prescribed. The primary goals of therapy are to maintain sinus rhythm (normal heart rhythm) and to reduce the occurrence of episodes of atrial fibrillation. Azimilide may have an effect on increasing the time to first recurrence of symptomatic atrial fibrillation or atrial flutter and symptomatic paroxysmal supraventricular tachycardia (other types of abnormal heart rhythms).

This double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of azimilide compared with placebo in maintaining sinus rhythm in patients who require cardioversion (electric shock to correct heart rhythm) to reduce atrial fibrillation. Once this phase of the study is completed, a second phase with a different study design will be conducted. The second phase is an open-label follow-up phase to the study. This follow-up phase will continue to evaluate the long-term efficacy and safety of a daily oral dose of azimilide in patients who complete the double-blind, placebo-controlled phase of this study.


Eligibility Criteria:
Inclusion criteria:

* Documented (12-lead ECG) history of symptomatic atrial fibrillation occurring between 48 hours and 6 months before screening
* Require the procedure of cardioversion (electric shock to correct heart rhythm)
* In the investigator's opinion, be likely to maintain sinus rhythm after cardioversion.
* Be anticoagulated according to the recommendations of the Study Group on Atrial Fibrillation of the European Society of Cardiology guidelines.

Exclusion criteria:

* Previously unsuccessful electrical cardioversions
* Failed to respond to any Class III antiarrhythmic drugs
* Qualifying arrhythmia due to acute reversible illness, acute myocardial infarction, and/or cardiac or thoracic surgery within one month prior to randomization
Penicillin Allergy De-Labelling in Elective Surgical Patients (PADLES)

Penicillin antibiotics are safe and inexpensive, and target selected bacteria rather than killing a broad range. Unfortunately, around 10% of the population are labelled as 'penicillin allergic'. This is often based on side effects such as rash and diarrhoea, and 90-95% of people with the label are not actually allergic to the drug.

The label leads to the use of alternative antibiotics, which tend to more toxic, and less specific about which bacteria they kill; this increases the risk of infections with so-called 'super-bugs', compared to patients without the label. People with the label also have an increased length of hospital stay and rates of readmission. These are significant problems for individuals, as well as wider society. Where the diagnosis is in doubt, the gold standard test for allergy is an oral challenge. Patients undergo skin +/- blood tests prior to a challenge, as these can help make the diagnosis. This combined pathway is expensive and time consuming, so testing cannot be offered routinely to all patients. However in patients with 'historic' reactions (many years previously), skin and blood tests become much less useful; in one study, 100% of patients who skin tested positive for amoxycillin allergy, tested negative 5 years later. Patients with historic reactions can therefore proceed directly to an oral challenge without prior skin or blood testing, since these offer little help in making the diagnosis. This streamlines the pathway, making it quick, non-invasive and cheap. Already established practice in several centres in Europe and beyond, this abbreviated pathway is offered on an ad-hoc basis in some centres in the UK.

The aim is to demonstrate that this pathway offers a safe and effective way to perform large-scale delabelling of elective surgical patients, who might not otherwise meet NICE criteria for testing.


Eligibility Criteria:
Inclusion Criteria:

* Allergic history is historic (more than 10 years ago) and suggestive of a non-immediate reaction or side effect
* Requires penicillin as first-line treatment for their planned surgery
* \>18 years
* Willing and able to give consent

Exclusion Criteria:

* Not willing to participate
* History suggestive of immediate type reaction (anaphylaxis)
* History of toxic epidermal necrolysis or Stevens Johnson syndrome
* Pregnant, planning to become pregnant during study, or breastfeeding
A Pilot Tele-rehabilitation Trial for Breast Cancer Survivors

Breast cancer is the leading cancer affecting women in Singapore. Breast cancer survivors commonly experience declined physical function and quality of life, due to their upper limb morbidity and wound issues post-surgery. Rehabilitation therapy can address the aforementioned issues that the survivors may experience during their recovery. No therapy however, can be effective if patients do not utilize them. Home-based telehealth (e.g., tele-rehabilitation) self-managed by patients and guided by healthcare professionals can potentially improve the service use and recovery. This study aims to understand the lived experience of post-mastectomy tele-rehabilitation and recovery process among female patients who undergo a unilateral mastectomy for breast cancer.


Eligibility Criteria:
Inclusion Criteria:

* Female 21 years and over
* Underwent a recent unilateral breast surgery (wide excision or simple mastectomy) with lymph nodes removed
* Speak and write English or Mandarin;
* No psychiatric history or chronic psychiatric condition as assessed by referring clinician

Exclusion Criteria:

* Having breast reconstruction
* Having legal blindness or severe visual impairment
* Having life expectancy of less than three months (12- weeks)
* Having previous upper limb injury or conditions that limit passive ranges of shoulder flexion (\<150°), elbow extension/flexion (0/145°)
Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma

Phase I trial to study the effectiveness of topotecan and radiation therapy in treating patients who have solid tumors or lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy with radiation therapy may kill more cancer cells.

OBJECTIVES:

I. Define the maximum tolerated dose and safety profile of topotecan (TOPO) administered with daily high-dose thoracic radiotherapy to a total of 60 Gy in patients with solid tumor or lymphoma.

II. Assess the qualitative and quantitative nature of the toxic effects encountered in this treatment.

III. Estimate the tissue and tumor TOPO concentrations during radiotherapy by evaluating plasma TOPO levels.

IV. Evaluate, using Western blot and immunohistochemical stain, the effects of TOPO/radiotherapy on topoisomerase I levels in peripheral blood lymphocytes (PBL).

V. Determine whether TOPO induces apoptosis in PBL from this patient population.

VI. Examine tumor tissue pre- and post-treatment (if available) for topoisomerase I levels, DNA damage, topoisomerase I/DNA complexes, and apoptotic events.

OUTLINE:

Radiosensitization plus Radiotherapy. Topotecan, TOPO, NSC-609699; plus external-beam irradiation using linear accelerators with photon energies between 4 and 10 MV (electrons acceptable for the boost field).

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Microscopically confirmed solid tumor or lymphoma not potentially curable by conventional surgery or radiotherapy
* Previously unirradiated disease scheduled to receive thoracic irradiation of up to 60 Gy, including pulmonary and esophageal tumors
* No metastatic disease more effectively treated by systemic chemotherapy
* No history of brain metastases

PATIENT CHARACTERISTICS:

* Age: 18 and over
* Performance status: ECOG 0 or 1
* WBC at least 4,000
* ANC at least 1,500
* Platelets at least 100,000
* Bilirubin no greater than 1.5 mg/dL
* Creatinine no greater than 1.5 mg/dL
* Calcium no greater than 11.0 mg/dL
* No pregnant or nursing women
* Pregnancy test required, as appropriate
* Effective contraception required of fertile patient

PRIOR CONCURRENT THERAPY:

* At least 4 weeks since chemotherapy (6 weeks since nitrosoureas and mitomycin) and recovered
* At least 4 weeks since radiotherapy and recovered
Nasogastric Tube Insertion Using Cook Airway Exchange Catheter in Anesthetized Patients

we first examined whether use of tube exchange catheter during NGT insertion could increase the success rate on the first attempt of NGT insertion compared with conventional technique. We then addressed the question of whether the use of tube exchange catheter might decrease the possible occurrence of complication associated with YOON insertion.


Eligibility Criteria:
Inclusion Criteria:

* ASA physical status of I or II who were scheduled to undergo elective surgery of gastrointestinal tract with NGT insertion under general anesthesia were enrolled

Exclusion Criteria:

* Patients with maxillofacial trauma, inability to adequately protect airway, and esophageal abnormalities were excluded. Pregnant patients were also excluded from the study.
Personalized Glucose Predictive and Therapy Advisory System - DIAdvisor 2

The primary purpose of this study is to see whether a tool that predict blood glucose and suggest therapy advices can help type 1 diabetic patients.

During this study, we would like to assess the efficacy in keeping blood glucose in a safe range (70-180 mg/dL) of the second generation of a Glucose Predictive and Therapy Advisory system in diabetic patients treated by basal-bolus insulin regimens using pumps or multiple daily injections. We want to compare the time spent in safe range while using the predictor and advisor outputs and when the patient is not using them. This is a randomized controlled crossover trial. Patient will come for two admissions of 3 days, one with the DIAdvisor system fully activated, and one with the prediction and advice features disabled.

Eligibility Criteria:
Inclusion Criteria:

1. Patient must be aged between 18 (inclusive) and 70 years old
2. Patients diagnosed with type 1 or type 2 diabetes according to WHO criteria for at least one year prior to study entry
3. Patient treated by a basal-bolus insulin therapy using an external pump or multiple-daily injections. The insulin regimen has to be stable for the previous six months. NPH insulin use will not be acceptable.
4. Patient should have stable diabetes with a HbA1c between ≥ 7.5 % and \< 10.5 % with no keto-acidosis for the previous 6 months.
5. Patient must have a Body Mass Index (BMI) lower than 35 Kg/m²
6. Patient must be willing to undergo all study procedures
7. Patient must be affiliated or beneficiary of a social medical insurance
8. Patient has signed informed consent form prior to study entry

Exclusion Criteria:

1. Patient is pregnant, or breast feeding during the period of the study
2. Patient has impaired renal function with a creatinine blood concentration over 150 μmol/L
3. Patient has a liver disease (ALAT, ASAT \> 2 x upper limit of normal range)
4. Patient is treated by sulfamides, GLP-1 analogues, DPP-IV inhibitors or glitazones
5. Alcohol or drug addiction, as identified by investigator during screening visit
6. Allergy to sensors or one of their components
7. Manifest psychological disorders
8. Patient health status is not compatible with physical exercise
9. Patient is actively enrolled in another clinical trial or was part of study within 30 days
10. Persons deprived of freedom, adults protected by law or vulnerable persons
Canadian Ticagrelor Survey

This study is designed to evaluate the effectiveness of the current ticagrelor risk minimisation strategy in Canada through a prescriber knowledge and understanding (KAU) survey of selected important identified safety concerns (i.e., bleeding, dyspnea and drug interactions) and ASA dosage.

Effectiveness of risk minimisation interventions for ticagrelor in Canada

Eligibility Criteria:
Inclusion Criteria:

- N/A (All prescribers will be contacted for participation)

Exclusion Criteria:

- Participation in a previous wave of the survey.
Prism Adaptation Therapy for Spatial Neglect

The purpose of this research study with a randomized controlled design is to examine the effects of prism adaptation treatment on two visual-spatial recovery components. After a stroke, an "internal GPS", locating where objects or people lie in a particular area of space, may be impaired. Alternately, a stroke may impair precise visual-spatial hand and body aiming movements. The research team wishes to discover whether prism adaptation treatment (two weeks of daily 20-min sessions of goal-directed movement with prism goggles) affects visual-spatial where or aiming errors selectively after stroke.

This research represents one of the first attempts to apply what we know about the brain from neuroscience research, to modern clinical rehabilitation practices.

The purpose of this research study with a randomized controlled design is to examine the effects of prism adaptation treatment on two visual-spatial recovery components. After a stroke, an "internal GPS", locating where objects or people lie in a particular area of space, may be impaired. Alternately, a stroke may impair precise visual-spatial hand and body aiming movements. The research team wishes to discover whether prism adaptation treatment (two weeks of daily 20-min sessions of goal-directed movement with prism goggles) affects visual-spatial where or aiming errors selectively after stroke.

This research represents one of the first attempts to apply what we know about the brain from neuroscience research, to modern clinical rehabilitation practices.

Eligibility Criteria:
Inclusion Criteria:

* The subject is 18 to 100 years of age, inclusive.
* The subject has had a stroke on the right side of the brain.
* The subject is able to give Informed consent.
* The subject has a spatial neglect (if known).
* The subject is able and willing to comply with the study protocol, including availability for all scheduled clinic visits.

Exclusion Criteria:

* The subject has or had a serious brain condition other than stroke.
Influencing Factors in Uveitis

Environmental factors possibly influencing uveitis are evaluated.

Smoking, nutrition, BMI, education

Eligibility Criteria:
Inclusion Criteria:

* Patients with Uveitis

Exclusion Criteria:

* Children under 18 years
NGS Genome Analysis in Personalisation of Lung Cancer Treatment

The identification of driver mutations in the epidermal growth factor receptor (EGFR) as the primary oncogenic event in a subset of lung adenocarcinomas led to a model of targeted treatment and genetic profiling of the disease. EGFR tyrosine kinase inhibitors (TKIs) confer remission in some patients, but use of the EGFR-TKIs is limited to patients with adenocarcinomas who have known activating EGFR mutations. And resistance to TKI treatment has become an increasingly important cause of treatment failure. Therefore, identification of the molecular components involved could lead to the development of effective therapy. Today only a limited number of genetic alterations are studied.

Next Generation Sequencing (NGS) has the potential of becoming an important tool in clinical and therapeutic decision-making in oncology owing to its enhanced sensitivity in DND mutation detection.


Eligibility Criteria:
Inclusion Criteria:

* patients of bronchial adénocarcinoma with metastases can benefit from first-line therapy - targeted therapy by tyrosine kinase inhibitor(TKI) for EGFR mutation and chemotherapy for non EGFR mutation)
* Patients with epidermoid cancer of the lungs can benefit from chemotherapy
* man and women
* age ≥ 18 years
* Patients have signed a written informed consent form
* Patients are affiliated to s social health insurance

Exclusion Criteria:

* Survival time ≤ 3 months
* Patients with cerebral metastases
* Patients could not benefit from treatment for others diseases
* Pregnancy or breast-feeding
* Incapacity to sign the consent form for psychiatric, behavioural disorders
* Private individuals of freedom or under tutelage